key: cord-0893824-jf9eql4a
authors: Wu, Yi; Shen, Yanqiong; Wu, Namei; Zhang, Xinghai; Chen, Shaohong; Yang, Chang; Zhou, Junhui; Wu, Yan; Chen, Da; Wang, Li; Wang, Yuye; Xu, Jiejie; Liu, Ke; Wang, Chao; Zhang, Huajun; Xia, Ninuo; Chiu, Sandra; Wang, Yucai
title: Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
date: 2022-03-01
journal: bioRxiv
DOI: 10.1101/2022.03.01.481391
sha: 7d520594d0dfa89aae792e0b5764fc535bda1de5
doc_id: 893824
cord_uid: jf9eql4a

SARS-CoV-2 has infected more than 400 million people around the globe and caused millions of deaths. Since its identification in November 2021, Omicron, a highly transmissible variant, has become the dominant variant in most countries. Omicron’s highly mutated spike protein, the main target of vaccine development, significantly compromises the immune protection from current vaccination. We develop an mRNA vaccine (SOmicron-6P) based on an Omicron-specific sequence. In mice, SOmicron-6P shows superior neutralizing antibodies inducing abilities to a clinically approved inactivated virus vaccine, a clinically approved protein subunit vaccine, and an mRNA vaccine (SWT-2P) with the same sequence of BNT162b2 RNA. Significantly, SOmicron-6P induces a 14.4∼27.7-fold and a 28.3∼50.3-fold increase of neutralizing activity against the pseudovirus of Omicron and authentic Omicron compared to SWT-2P, respectively. In addition, two doses SOmicron-6P significantly protects Syrian hamsters against challenge with SARS-CoV-2 Omicron variant and elicits high titers of nAbs in a dose-dependent manner in macaques. Our results suggest that SOmicron-6P offers advantages over current vaccines, and it will be helpful for those with weak immunity.

Data are shown as mean ± SEM. Significance was calculated using one-way ANOVA 130 with multiple comparisons tests (n.s., not significant, *p < 0.05, **p < 0.01, ***p < 131 0.001, ****p < 0.0001) 132 133 We next investigated T cell responses in mice received two doses of SOmicron-6P. 134 For T cell analysis in spleens, although the ratios of CD4 + and CD8 + T cells within 135 CD45 + leukocytes remain unchanged, SOmicron-6P elicited significant increases in 136 activated CD4 + (CD69 + CD4 + ) and CD8 + (CD69 + CD8 + ) T cells (Figure 2A , 2B, and 137 Figure S7 ). We also noted that cytotoxic CD8 + T cells (CD107a + and Granzyme B + ), 138 which play a crucial role in eliminating infected cells, have increased significantly after 139 vaccination (Figure 2C and 2D) . Furthermore, in the spleen of SOmicron-6P immunized 9 mice, we observed extensive expansion of the effector memory CD4 + and CD8 + T cells 141 (CD44 + CD62L -), which mediate protective memory (Figure 2E and 2F) . 142 Previous data indicate that mRNA vaccines induce T-helper-1 (Th1) -driven CD4 + 143 T-cell responses (Laczko et al., 2020; Vogel et al., 2021) . To investigate whether our 144 SOmicron-6P activates an immune response similarly, we collected splenocytes from the 145 immunized mice and re-stimulated them with the full-length S peptide mix. Using an 146 enzyme-linked immunosorbent spot (ELISPOT) assay, we detected high levels of γ and interleukin-2 (IL-2) secreting Th1 cells in SOmicron-6P immunized mice (Figure 148 2G and 2H). Nevertheless, no significant difference in T-helper-2 (Th2) cytokines 

Female BALB/c mice were immunized with 0, 1, 5 or 10 µg SOmicron-6P. Twenty-nine 158 days after the first immunization, mice were euthanized and their spleens were collected 159 for T cell response and phenotyping analysis. were harvested and re-stimulated with SARS-CoV-2 S protein peptide mix for 24 h on 168 day 29 after first immunization.

Data are shown as mean ± SEM. Significance was calculated using one-way ANOVA 170 with multiple comparisons tests (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)

The Syrian hamster has been demonstrated as a suitable animal model for SARS-

CoV-2 infection (Munoz-Fontela et al., 2020) . Five groups of hamsters were vaccinated 174 on day 0 and day 21 with either 1, 10, 25, and 50 µg of SOmicron-6P or PBS. The hamster 175 sera were collected and evaluated for vaccine immunogenicity on day 14, 21 and 28 176 (Figure 3A) . A significant amount of IgG against S protein was detected on day 14 and 177 21 after the first immunization, but no apparent dose-dependency was observed.

However, the second dose boosts S antibodies more than ten times one week later (on 179 day 28) (Figure 3B and S9) . The pseudovirus assay showed that high neutralizing 180 antibody titers were elicited even by 1 µg dose of SOmicron-6P (Figure 3C and S10). In 181 line with this, high levels of neutralizing activity against authentic Omicron in SOmicron-182 6P vaccinated animals ( Figure 3D ). Moreover, we observed a strong correlation of 183 pseudovirus assay with the authentic Omicron neutralization assay, with a correlation 184 co-efficiency of 0.91 ( Figure 3E ).

On day 30, some hamsters were challenged with 1 × 10 4 plaque-forming units 186 (PFU) of authentic Omicron virus via intranasal route and sacrificed 4 days later. As 187 shown in Figure 3F , only a trace amount of viral RNA was detected in the lung tissue 188 of vaccinated animals with a little more for the 1 g group, which is a 4-5 magnitude 189 reduction than the control group. Infectious virus in lung tissue was determined with Data are shown as mean ± SEM. Significance was calculated using one-way ANOVA 218 with multiple comparisons tests (n.s., not significant, *p < 0.05, **p < 0.01, ***p < 219 0.001, ****p < 0.0001).

The immunogenicity of SOmicron-6P was also evaluated in non-human primates.

Macaques were immunized with either 20 or 100 µg of SOmicron-6P twice at a 21-day 223 interval ( Figure 4A ). Similar to the results in mice and hamsters, the first immunization 224 generates some level of IgG and almost no nAbs, with only one macaque producing 225 little nAbs . However, one week after the second 226 immunization, all the macaques responded vigorously to the second immunization in 227 one week and kept producing higher nAbs on day 35. Consistent with this, sera of the 228 macaques showed vigorous neutralization activity against authentic Omicron on both 229 day 28 and 35 ( Figure 4D ). Finally, we tested whether the nAbs elicited by SOmicron-6P 230 could provide cross-protection against other SARS-CoV-2 variants. Although SOmicron-231 6P vaccinated macaques produced high nAbs against the Omicron variants, we detected 232 relatively lower nAbs production against the wild-type, Beta, or Delta variants (Figure 233 4E-4G). Note that the experimental settings of our study are different from these studies. We 291 compare the immune protection effect against Omicron between Omicron-specific 292 mRNA vaccines and wild type mRNA vaccines on naïve animals that have not been 293 exposed to any of the prior vaccines. Our data provide strong evidence to show that 294 Omicron-specific mRNA vaccines elicit enhanced protection for naïve animals. We 295 think that highly the mutated S protein of Omicron has significantly compromised the The plaque reduction neutralization assay was carried out as described before (Wang et   566 al., 2020). Sera were inactivated at 56°C for 30 min before use. The sera were diluted 567 150-fold first, and then 3-fold serial dilutions were prepared in the maintenance medium. 

Clinically Approved Inactivated Virus Vaccine Rarely Induced nAbs 718

Against SARS-CoV-2 Omicron Variant in Mice

A-B) Neutralization curves of (A) 50, and (B) 100 μL inactivated virus vaccine

µL/vial for an adult) induced antibodies against pseudotyped and replication-deficient 721 SARS-CoV-2 Omicron